8-Hydroxyquinoline cMLCK Activators for Calcium-Independent Inotropy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing inotropic agents for heart failure, such as catecholamine and PDE3 inhibitors, worsen prognosis due to side effects like ischemia, arrhythmia, and sudden death by increasing intracellular calcium concentration, while newer agents like omecamtiv mecarbil have concerns for ischemic heart failure, and there is a need for a compound that enhances myocardial contractility without increasing cellular calcium.

Innovation Solution

An 8-hydroxyquinoline compound is synthesized to activate cardiac-specific myosin regulatory light chain kinase (cMLCK), increasing phosphorylation of myosin regulatory light chain (MLC2) and enhancing myocardial contractility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Power

If conventional inotropic agents (catecholamine and PDE3 inhibitors) are used to enhance myocardial contractility, then contractility is improved, but side effects (ischemia, arrhythmia, sudden death) occur due to increased intracellular calcium concentration

Engineering Contradiction:

Improvemyocardial contractilityVSAvoidside effects (ischemia, arrhythmia, sudden death)

Core Design Contradiction:

PowerVSObject-affected harmful factors

Solution Approach 1:

The patent introduces cMLCK (cardiac myosin regulatory light chain kinase) as an intermediary mechanism to achieve myocardial contractility enhancement without directly increasing intracellular calcium. Instead of using calcium-dependent pathways (conventional inotropic agents), the invention activates cMLCK which phosphorylates MLC2 (myosin regulatory light chain), providing a calcium-independent pathway for improving contractility and avoiding calcium-related side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameter pathway from calcium concentration-dependent to phosphorylation-dependent. By targeting the phosphorylation state of MLC2 through cMLCK activation rather than calcium levels, the invention achieves contractility improvement through a different physiological parameter, thereby avoiding the harmful effects associated with calcium overload

Inventive Principle:

Principle #35Parameter changes

2Power

If omecamtiv mecarbil is used to enhance myocardial contractility without increasing intracellular calcium, then contractility is improved without worsening prognosis in phase 3 trial, but concerns remain regarding administration to patients with ischemic heart failure

Engineering Contradiction:

Improvemyocardial contractilityVSAvoidsafety in ischemic heart failure

Core Design Contradiction:

PowerVSReliability

Solution Approach 1:

The patent uses cMLCK activation as an intermediary mechanism that is fundamentally different from omecamtiv mecarbil's direct myosin activation approach. By targeting the upstream kinase (cMLCK) rather than the myosin directly, the invention provides a more selective cardiac-specific pathway that may offer improved safety profile, particularly for ischemic heart failure patients

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260103444A18-hydroxyquinoline compound and use thereof

Publication Date: 2026.04.16 OSAKA UNIVERSITY

AI summary

An object of the present invention is to provide a cMLCK activator that can enhance myocardial contractility without an increase in cellular calcium concentration. This object is achieved by a cMLCK activator containing an 8-hydroxyquinoline compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof,whereinR1 represents hydrogen or the like;R2 represents R7CO— (R7 is C1-6 alkyl or the like) or the like;R3 represents hydrogen; andR4, R5, and R6 represent hydrogen or the like.